 |
alendronate |
|---|---|
| Trade Name | Fosamax |
| Orphan Indication | Osteogenesis imperfecta |
| USA Market Approval | USA |
| USA Designation Date | 2003-03-31 00:00:00 |
| Sponsor | Merck, Sharpe & Dohme Corp.;126 East Lincoln Ave., RY 33-212;Rahway, New Jersey, 07065 |
Related Access Program
Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia
Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia
AbbVie – Acute Myeloid Leukemia (AML)
University of California, San Francisco – Acute Myeloid Leukemia
Emory University – Acute Myeloid Leukemia
British Columbia Cancer Agency – Thyroid Cancer, Medullary
Novartis Pharmaceuticals – Acute Myeloid Leukemia (AML) With
Beijing Cancer Hospital – Thyroid Nodules
Alnylam Pharmaceuticals – Amyloidosis, Hereditary
Alnylam Pharmaceuticals – TTR-mediated Amyloidosis
Astellas Pharma Global Development, Inc. – Acute Myeloid Leukemia (AML)